Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.

Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024 Jan; 11(1):e15-e26.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
Female
Humans
Leukemia, Myelomonocytic, Chronic
Male
Myelodysplastic Syndromes
Pneumonia
Treatment Outcome

authors with profiles

Olatoyosi Odenike